BLES Biochemicals

What BLES Biochemicals does

BLES Biochemicals Inc. is a privately-held Canadian specialty pharmaceutical company, incorporated in 1992 and headquartered in London, Ontario. The company manufactures and distributes BLES® (bovine lipid extract surfactant), a pulmonary surfactant extracted from bovine lung surfactant using an intact lung lavage process that preserves the natural ratio of surfactant-associated proteins SP-B and SP-C to phospholipids. The product is administered via intratracheal instillation at 27 mg phospholipid/mL and is indicated for the treatment of Neonatal Respiratory Distress Syndrome (NRDS / Hyaline Membrane Disease) in premature infants in highly supervised hospital clinical settings.

The company's commercial model is a B2B specialty pharmaceutical sales operation targeting hospital Neonatal Intensive Care Units (NICUs). BLES® is sold directly to hospitals under quote-based, multi-year contracts; the company's website is gated to verified medical professionals, and pricing is not publicly disclosed. BLES Biochemicals holds Health Canada approval (granted 2002) and is the market leader for pulmonary surfactant in Canada. In India the product is marketed as Neosurf through a partnership with Cipla, where it holds the #1 surfactant position. The company also maintains BLESCath as a related catheter brand for surfactant administration. Over 160,000 patients have been treated with BLES® worldwide and more than 9,000 patients have been enrolled in associated clinical trials.

Operationally, BLES Biochemicals operates as a focused manufacturing and distribution entity with 11–50 employees, no disclosed external institutional investors, and no parent company. The founders — Dr. Fred Possmayer, Dr. David Bjarneson, and Dr. Harold Nigh — have remained with the company since incorporation and have chosen to keep the business private to preserve product and corporate integrity. Global expansion has been underway since 2006, supported by the company's multi-language (English, French, Spanish) presence and an established track record of cross-jurisdictional regulatory filings. The discovery underlying BLES® was recognized by the Council of Ontario Universities as one of the top five university discoveries in Ontario, alongside insulin.

Name

BLES Biochemicals

Legal name

BLES Biochemicals Inc.

Website

https://blesbiochem.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: BLES Biochemicals manufactures and distributes BLES®, a specialty pharmaceutical product for neonatal respiratory distress syndrome treatment. The product is sold directly to hospitals and NICUs. No generic form exists, creating a proprietary market position.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

BLES Biochemicals Inc. manufactures and distributes BLES® (bovine lipid extract surfactant), a pulmonary surfactant extracted from bovine lung surfactant for the treatment of Neonatal Respiratory Distress Syndrome (NRDS/Hyaline Membrane Disease) in premature infants. The product is administered via intratracheal instillation in highly supervised clinical settings such as hospital NICUs at a 5mL/kg dose of 27mg phospholipid/mL, and is sold directly to hospitals with no generic equivalent available on the market.

Product overview

BLES Biochemicals Inc. is a privately-owned Canadian pharmaceutical company that manufactures and distributes pulmonary surfactant products for neonatal respiratory care. The company's primary product is BLES® (bovine lipid extract surfactant), a therapeutic agent extracted from bovine lung surfactant. BLES® is a unique product with no generic equivalent, designed for intratracheal instillation in premature infants suffering from Neonatal Respiratory Distress Syndrome. The company also markets its product under the brand name Neosurf in India through a partnership with Cipla, and maintains an associated brand called BLESCath. BLES Biochemicals operates as the market leader for pulmonary surfactant in Canada and has expanded distribution globally since 2006.

Differentiator

Problem solved

Functional benefit

Brands

• BLESCath: Catheter brand related to surfactant administration

Products and services

• BLES® (bovine lipid extract surfactant) A pulmonary surfactant extracted from bovine lung surfactant using an intact lung lavage process that removes hydrophilic proteins (primarily SP-A) and selects for hydrophobic phospholipids and SP-B and SP-C. Administered via intratracheal instillation at 5mL/kg of 27mg phospholipid/mL for treatment of Neonatal Respiratory Distress Syndrome (NRDS/Hyaline Membrane Disease) in premature infants in highly supervised clinical settings such as hospital NICUs.
• Neosurf The brand name under which BLES® (bovine lipid extract surfactant) is marketed in India through a partnership with Cipla for treatment of neonatal respiratory distress syndrome in premature infants.
• BLESCath An associated catheter brand related to surfactant administration, made available by BLES Biochemicals Inc. via the BLESCath website.

Quantifiable outcome

• Reduced neonatal mortality from over 50% to less than 2%
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• CiplacoreChannel Partner/ Reseller/ Distributor · 1 January 2000In the early 2000s, BLES Biochemicals was introduced to Cipla in India. Together, the two companies registered the product in India under the brand name Neosurf, obtaining marketing authorization within a year. Neosurf became and remains the number one surfactant in the Indian market. This partnership enabled BLES Biochemicals to expand into one of the world's largest pharmaceutical markets.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• AbbVie: Global pharmaceutical major that historically marketed Survanta (beractant), a bovine-derived pulmonary surfactant. While Survanta has been divested, AbbVie represents a broad incumbent with overlapping neonatal respiratory capabilities.

Direct peers

• Boehringer Ingelheim: Global pharmaceutical company that markets Alveofact (bovine lung surfactant) in European and select international markets. A direct competitor in the bovine pulmonary surfactant category serving neonatal RDS patients.
• Chiesi Farmaceutici: Italian pharmaceutical company that manufactures Curosurf (porcine-derived pulmonary surfactant) for neonatal RDS. Closest direct competitor to BLES Biochemicals, serving the same NICU customer base with a similar animal-derived surfactant product.
• ONY Biotech: US-based specialty pharma that produces Infasurf (calf lung surfactant extract), a bovine-derived pulmonary surfactant for neonatal RDS. Directly competes with BLES in the same therapeutic category using a similar bovine-source manufacturing approach.

Others

• Drägerwerk: German medical technology company that manufactures neonatal ventilators, incubators, and respiratory support equipment used in NICUs alongside surfactant therapy. An ecosystem participant in neonatal respiratory care rather than a direct drug competitor.
• Getinge: Swedish medtech company providing NICU infrastructure including neonatal ventilators, resuscitation equipment, and patient warming systems. Adjacent participant in the neonatal care ecosystem where BLES is administered.
• Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company with a history in neonatal and respiratory therapeutics. Operates in adjacent specialty pharma segments relevant to BLES's hospital-channel distribution model.

Emerging players

• Discovery Laboratories: Biopharmaceutical company that developed Surfaxin (lucinactant), a synthetic peptide-based pulmonary surfactant for neonatal RDS. Represents the synthetic-surfactant competitive angle to animal-derived products like BLES.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bles-biochemicals-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BLES Biochemicals